Galectin-10 antibodies

Patent metadata

Field	Value
Publication number	US-11713354-B2
Application number	US-202117194950-A
Country	US
Kind code	B2
Filing date	Mar 8, 2021
Priority date	Apr 13, 2018
Publication date	Aug 1, 2023
Grant date	Aug 1, 2023

Abstract

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

First claim

The invention claimed is:

1. A method of inhibiting galectin-10 crystal formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein the subject has a disease or condition selected from the group consisting of asthma; chronic rhinosinusitis; celiac disease; helminth infection; gastrointestinal eosinophilic inflammation; cystic fibrosis (CF); allergic bronchopulmonary aspergillosis (ABPA); Churg-Strauss vasculitis; chronic eosinophilic pneumonia; and acute myeloid leukemia, and wherein the antibody or antigen binding fragment thereof cross competes for binding to human galectin-10 with an antibody or antigen binding fragment thereof comprising a variable heavy chain domain (VH) and a variable light chain domain (VL) wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:
(i) HCDR3 comprising SEQ ID NO: 3, HCDR2 comprising SEQ ID NO: 2, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 58, LCDR2 comprising SEQ ID NO: 57, and LCDR1 comprising SEQ ID NO: 56;
(ii) HCDR3 comprising SEQ ID NO: 9, HCDR2 comprising SEQ ID NO: 8, HCDR1 comprising SEQ ID NO: 7, LCDR3 comprising SEQ ID NO: 64, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 62;
(iii) HCDR3 comprising SEQ ID NO: 12, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 10, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65;
(iv) HCDR3 comprising SEQ ID NO: 25, HCDR2 comprising SEQ ID NO: 24, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 77, and LCDR1 comprising SEQ ID NO: 76;
(v) HCDR3 comprising SEQ ID NO: 47, HCDR2 comprising SEQ ID NO: 46, HCDR1 comprising SEQ ID NO: 45, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;
(vi) HCDR3 comprising SEQ ID NO: 43, HCDR2 comprising SEQ ID NO: 42, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 92;
(vii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 44, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 97, LCDR2 comprising SEQ ID NO: 96, and LCDR1 comprising SEQ ID NO: 95;
(viii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 52, HCDR1 comprising SEQ ID NO: 51, LCDR3 comprising SEQ ID NO: 98, LCDR2 comprising SEQ ID NO: 97, and LCDR1 comprising SEQ ID NO: 80;
(ix) HCDR3 comprising SEQ ID NO: 55, HCDR2 comprising SEQ ID NO: 54, HCDR1 comprising SEQ ID NO: 53, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;
(x) HCDR3 comprising SEQ ID NO: 50, HCDR2 comprising SEQ ID NO: 49, HCDR1 comprising SEQ ID NO: 48, LCDR3 comprising SEQ ID NO: 96, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 95;
(xi) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 5, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 61, LCDR2 comprising SEQ ID NO: 60, and LCDR1 comprising SEQ ID NO: 59;
(xii) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 182, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180;
(xiii) HCDR3 comprising SEQ ID NO: 174, HCDR2 comprising SEQ ID NO: 173, HCDR1 comprising SEQ ID NO: 172, LCDR3 comprising SEQ ID NO: 189, LCDR2 comprising SEQ ID NO: 188, and LCDR1 comprising SEQ ID NO: 180; and
(xiv) HCDR3 comprising SEQ ID NO: 165, HCDR2 comprising SEQ ID NO: 164, HCDR1 comprising SEQ ID NO: 163, LCDR3 comprising SEQ ID NO: 193, LCDR2 comprising SEQ ID NO: 181, and LCDR1 comprising SEQ ID NO: 180.

2. A method of inhibiting galectin-10 crystal formation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof which specifically binds to human galectin-10, wherein:
(a) the antibody or antigen binding fragment thereof comprises a VH and a VL wherein the VH and VL domains comprise the CDR sequences selected from the group consisting of:
(i) HCDR3 comprising SEQ ID NO: 3, HCDR2 comprising SEQ ID NO: 2, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 58, LCDR2 comprising SEQ ID NO: 57, and LCDR1 comprising SEQ ID NO: 56;
(ii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 5, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 61, LCDR2 comprising SEQ ID NO: 60, and LCDR1 comprising SEQ ID NO: 59;
(iii) HCDR3 comprising SEQ ID NO: 9, HCDR2 comprising SEQ ID NO: 8, HCDR1 comprising SEQ ID NO: 7, LCDR3 comprising SEQ ID NO: 64, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 62;
(iv) HCDR3 comprising SEQ ID NO: 12, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 10, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65;
(v) HCDR3 comprising SEQ ID NO: 15, HCDR2 comprising SEQ ID NO: 14, HCDR1 comprising SEQ ID NO: 13, LCDR3 comprising SEQ ID NO: 70, LCDR2 comprising SEQ ID NO: 69, and LCDR1 comprising SEQ ID NO: 68;
(vi) HCDR3 comprising SEQ ID NO: 18, HCDR2 comprising SEQ ID NO: 17, HCDR1 comprising SEQ ID NO: 16, LCDR3 comprising SEQ ID NO: 72, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 71;
(vii) HCDR3 comprising SEQ ID NO: 20, HCDR2 comprising SEQ ID NO: 19, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 75, LCDR2 comprising SEQ ID NO: 74, and LCDR1 comprising SEQ ID NO: 73;
(viii) HCDR3 comprising SEQ ID NO: 23, HCDR2 comprising SEQ ID NO: 22, HCDR1 comprising SEQ ID NO: 21, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 65;
(ix) HCDR3 comprising SEQ ID NO: 25, HCDR2 comprising SEQ ID NO: 24, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 77, and LCDR1 comprising SEQ ID NO: 76;
(x) HCDR3 comprising SEQ ID NO: 28, HCDR2 comprising SEQ ID NO: 27, HCDR1 comprising SEQ ID NO: 26, LCDR3 comprising SEQ ID NO: 67, LCDR2 comprising SEQ ID NO: 66, and LCDR1 comprising SEQ ID NO: 79;
(xi) HCDR3 comprising SEQ ID NO: 31, HCDR2 comprising SEQ ID NO: 30, HCDR1 comprising SEQ ID NO: 29, LCDR3 comprising SEQ ID NO: 81, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 80;
(xii) HCDR3 comprising SEQ ID NO: 33, HCDR2 comprising SEQ ID NO: 32, HCDR1 comprising SEQ ID NO: 1, LCDR3 comprising SEQ ID NO: 84, LCDR2 comprising SEQ ID NO: 83, and LCDR1 comprising SEQ ID NO: 82;
(xiii) HCDR3 comprising SEQ ID NO: 36, HCDR2 comprising SEQ ID NO: 35, HCDR1 comprising SEQ ID NO: 34, LCDR3 comprising SEQ ID NO: 87, LCDR2 comprising SEQ ID NO: 86, and LCDR1 comprising SEQ ID NO: 85;
(xiv) HCDR3 comprising SEQ ID NO: 38, HCDR2 comprising SEQ ID NO: 11, HCDR1 comprising SEQ ID NO: 37, LCDR3 comprising SEQ ID NO: 78, LCDR2 comprising SEQ ID NO: 63, and LCDR1 comprising SEQ ID NO: 88;
(xv) HCDR3 comprising SEQ ID NO: 41, HCDR2 comprising SEQ ID NO: 40, HCDR1 comprising SEQ ID NO: 39, LCDR3 comprising SEQ ID NO: 91, LCDR2 comprising SEQ ID NO: 90, and LCDR1 comprising SEQ ID NO: 89;
(xvi) HCDR3 comprising SEQ ID NO: 43, HCDR2 comprising SEQ ID NO: 42, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 92;
(xvii) HCDR3 comprising SEQ ID NO: 6, HCDR2 comprising SEQ ID NO: 44, HCDR1 comprising SEQ ID NO: 4, LCDR3 comprising SEQ ID NO: 97, LCDR2 comprising SEQ ID NO: 96, and LCDR1 comprising SEQ ID NO: 95;
(xviii) HCDR3 comprising SEQ ID NO: 47, HCDR2 comprising SEQ ID NO: 46, HCDR1 comprising SEQ ID NO: 45, LCDR3 comprising SEQ ID NO: 94, LCDR2 comprising SEQ ID NO: 93, and LCDR1 comprising SEQ ID NO: 71;
(xix) HCDR3 c

Assignees

• Argenx Iip Bv
• Vib Vzw
• Univ Gent
• argenx BV

Inventors

• Percier Jean-Michel
• Blanchetot Christophe
• Saunders Michael
• De Haard Hans
• Van Der Woning Sebastian
• Persson Emma
• Lambrecht Bart
• Savvides Savvas
• Hammad Hamida
• Verstraete Kenneth

Classifications

• C07K16/2851 Primary

  against the lectin superfamily, e.g. CD23, CD72 · CPC title

• G01N33/68

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title